Arylamine N-acetyltransferase activity in man

Drug Metabolism Reviews

Volumn 31, Issue 2, 1999, Pages 489-502

  Cascorbi, Ingolf ^a   Brockmöller, Jürgen ^a   Mrozikiewicz, Przemyslaw M ^a   Müller, Antje ^a   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; AMONAFIDE; AMRINONE; ARYLAMINE ACETYLTRANSFERASE; ARYLAMINE N ACETYLTRANSFERASE 1; ARYLAMINE N ACETYLTRANSFERASE 2; CAFFEINE; CLONAZEPAM; DAPSONE; HYDRALAZINE; ISONIAZID; NITRAZEPAM; PROCAINAMIDE; SALAZOSULFAPYRIDINE; SULFADIMIDINE; UNCLASSIFIED DRUG;

CANCER RISK; CONFERENCE PAPER; DRUG ACETYLATION; DRUG METABOLISM; ENZYME ACTIVITY; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PHENOTYPE; RISK FACTOR;

EID: 0344759188     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-100101932     Document Type: Conference Paper

References (47)

1. N. P. Lang, M. A. Butler, J. Massengill, M. Lawson, R. C. Stotts, M. E. A. Hauer-Jensen, and F. F. Kadlubar, Cancer Epidemiol. Biomark. Prev., 3, 675-682 (1994).
2. D. A. P. Evans, in Pharmacogenetics of Drug Metabolism (W. Kalow, ed.), Pergamon Press, New York, 1992, pp. 95-197.
3. D. M. Grant, B. K. Tang, and W. Kalow, Br. J. Clin. Pharmacol., 17, 459-464 (1984).
4. Y. C. Bechtel, C. Bonaiti-Pellie, N. Poisson, J. Magnette, and P. R. Bechtel, Clin. Pharmacol. Ther., 54, 134-141 (1993).
5. K. P. Vatsis and W. W. Weber, Arch. Biochem. Biophys., 301, 71-76 (1993).
6. N. C. Hughes, S. A. Janezic, K. L. McQueen, M. A. S. Jewett, T. Castranio, D. A. Bell, and D. M. Grant, Pharmacogenetics, 8, 55-66 (1998).
7. N. Matas, P. Thygesen, M. Stacey, A. Risch, and E. Sim, Cytogenet. Cell. Genet., 77, 290-295 (1997).
8. M. Blum, D. M. Grant, W. McBride, M. Heim, and U. A. Meyer. DNA Cell Biol., 9, 193-203 (1990).
9. D. M. Grant, M. Blum, A. Demierre, and U. A. Meyer, Nucl. Acids Res., 17, 3589 (1989).
10. T. Deguchi, M. Mashimo, and T. Suzuki. J. Biol. Chem., 267, 18140-18147 (1992).
11. K. P. Vatsis, K. J. Martell, and W. W. Weber, Proc. Natl. Acad. Sci. USA, 88, 6333-6337 (1991).
12. D. A. Bell, J. A. Taylor, M. A. Butler, E. A. Stephens, J. Wiest, and G. W. Lucier, Carcinogenesis, 14, 1689-1692 (1993).
13. D. W. Hein, M. A. Doll, T. D. Rustan, and R. J. Ferguson, Cancer Res., 55, 3531-3536 (1995).
14. D. W. Hein, R. J. Ferguson, M. A. Doll, T. D. Rustan, and K. Gray, Hum. Mol. Gen., 3, 729-734 (1994).
15. I. Cascorbi, J. Brockmöller, P. M. Mrozikiewicz, S. Bauer, R. Loddenkemper, and I. Roots, Cancer Res., 56, 3961-3966 (1996).
16. J. A. G. Agúndez, M. Olivera, C. Martínez, J. M. Ladero, and J. Benítez, Pharmacogenetics, 6, 423-428 (1996).
17. C. Deloménie, L. Sica, D. M. Grant, R. Krishnamoorthy, and J. M. Dupret, Pharmacogenetics, 6, 177-185 (1996).
18. I. Cascorbi, N. Drakoulis, J. Brockmöller, A. Maurer, K. Sperling, and I. Roots, Am. J. Hum. Genet., 57, 581-592 (1995).
19. I. Cascorbi and I. Roots, Pharmacogenetics, 9 (1999).
20. K. P. Vatsis, W. W. Weber, D. A. Bell, J. M. Dupret, D. A. P. Evans, D. M. Grant, D. W. Hein, H. J. Lin, U. A. Meyer, M. V. Relling, E. Sim, T. Suzuki, and Y. Yamazoe, Pharmacogenetics, 5, 1-17 (1995).
21. D. Hickman and E. Sim, Biochem. Pharmacol., 42, 1007-1014 (1991).
22. D. M. Grant, Pharmacogenetics, 3, 45-50 (1993).
23. M. Mashimo, T. Suzuki, M. Abe, and T. Deguchi, Hum. Genet., 90, 139-143 (1992).
24. A. Risch, D. M. A. Wallace, S. Bathers, and E. Sim, Hum. Mol. Genet., 4, 231-236 (1995).
25. J. Brockmöller, I. Cascorbi, R. Kerb, and I. Roots, Cancer Res., 56, 3915-3925 (1996).
26. B. Lorenzo and M. M. Reidenberg, Br. J. Clin. Pharmacol., 28, 207-208 (1989).
27. A. E. Cribb, R. Isbrucker, T. Levatte, B. Tsui, C. T. Gillespie, and K. W. Renton, Pharmacogenetics, 4, 166-170 (1994).
28. M. Yamamoto, G. Sobue, M. Mukoyama, Y. Matsuoka, and T. Mitsuma, J. Neurol. Sci., 135, 51-54 (1996).
29. M. M. Reidenberg, M. Levy, D. E. Drayer, E. Zylber-Katz, and W. C. Robbins, Arthritis Rheum., 23, 569-573 (1980).
30. S. Shiokawa, M. Yasuda, and M. Nobunaga, Arthritis Rheum., 35, 1397-1399 (1992).
31. M. P. Ross, E. M. Allen-Webb, J. B. Pappas, and E. C. McGough, Clin. Pharmacol. Ther., 53, 661-667 (1993).
32. R. A. Cartwright, R. W. Glashan, H. J. Rogers, R. A. Ahmand, D. Barham-Hall, and E. Higgins, Lancet, 2, 842-845 (1982).
33. S. Henning, I. Cascorbi, V. Jahnke, and I. Roots, in Head and Neck Cancer. Advances in Basic Research (J. A. Werner, B. M. Lippert, and H. H. Rudert, eds.), Elsevier, Amsterdam, 1996, pp. 465-468.
34. I. Roberts-Thomson, P. Ryan, K. Khoo, W. Hart, A. McMichael, and R. Butler, Lancet, 347, 1372-1374 (1996).
35. J. P. Gil and M. C. Lechner, Carcinogenesis, 19, 37-41 (1998).
36. N. M. Probst-Hensch, R. W. Haile, S. A. Ingles, M. P. Longnecker, C. Y. Han, B. K. Lin, D. B. Lee, G. T. Sakamoto, H. D. Frankl, E. R. Lee, and H. J. Lin, Cancer Res., 55, 2017-2020 (1995).
37. C. B. Ambrosone, J. L. Freudenheim, S. Graham, J. R. Marshall, J. E. Vena, and J. R. Brasure, JAMA, 276, 1494-1501 (1996).
38. R. F. Minchin, Biochem. J., 307, 1-3 (1995).
39. D. W. Hein, M. A. Doll, T. D. Rustan, K. Gray, Y. Feng, and D. M. Grant, Carcinogenesis, 14, 1633-1638 (1993).
40. D. A. Bell, A. F. Badawi, P. Lang, K. F. Ilett, F. F. Kadlubar, and A. Hirvonen, Cancer Res., 55, 5226-5229 (1995).
41. N. M. Probst-Hensch, R. W. Haile, D. S. Li, G. T. Sakamoto, A. D. Louie, B. K. Lin, H. D. Frankl, E. R. Lee, and H. J. Lin, Carcinogenesis, 17, 2125-2129 (1996).
42. P. M. Mrozikiewicz, I. Cascorbi, J. Brockmöller, and I. Roots, Clin. Pharmacol. Ther., 59, 376-382 (1996).
43. A. S. Aynacioglu, I. Cascorbi, P. M. Mrozikiewicz, and I. Roots, Pharmacogenetics, 7, 327-331 (1997).
44. S. Henning, I. Cascorbi, B. Münchow, V. Jahnke, and I. Roots, Pharmacogenetics, 9 (1999).
45. M. A. Doll, W. Jiang, A. C. Deitz, T. D. Rustan, and D. W. Hein, Biochem. Biophys. Res. Commun., 233, 584-591 (1997).
46. N. E. Butcher, K. E. Ilett, and R. F. Minchin, Pharmacogenetics, 8, 67-72 (1998).
47. I. Cascorbi, S. Henning, J. Brockmöller, J. Mwinyi, S. Goebel, and I. Roots, unpublished.